Located in Barcelona, AB-BIOTICS started its probiotics research program 12 years ago setting its own collection of more than 1000 bacterial strains, sourced from different target places from all over the world. AB-BIOTICS has developed an innovative portfolio of clinically-documented strains targeting different medical indications, such as cardiovascular, pediatric, GI, dental health among others. AB-BIOTICS is currently present through local partners in 66 markets selling its probiotic products through local licensee partners.
In 2018, Kaneka has invested in AB-Biotics and started exclusive business partnership with AB-Biotics for production and sales of its probiotics products in US, Canada and Japan.
Read the latest AB-Biotics press release: New publication on AB-Kolicare®